The Association for Creatine Deficiencies (ACD) seeks support from the National Institutes of Health to be applied toward a two-day 2nd CCDS Scientific+Family Symposium at The Grand Summit Hotel in Park City, Utah on July 31 - August 1. The conference will welcome the world’s scientific and medical experts in ultra-rare, genetic Cerebral Creatine Deficiency Syndromes (CCDS), plus scientists in adjacent disease areas, a diverse group of early-career researchers, affected individuals, and families. The goal is to expand not only the understanding of the three types of CCDS, but also expand the CCDS community and progress toward establishing biomarkers, endpoints, and consensus guidelines for care of each of the three CCDS. At the conference, professionals will learn from families and patients while also presenting their experience and knowledge of GAMT, CTD, and AGAT disorders, allowing for a deeper understanding of CCDS in the medical community and helping pave the way for innovation through collaboration. The two-day Symposium will feature six scientific sessions covering topics including: - Basic science of creatine metabolism, current animal models, and preclinical studies; - Clinical overview of CCDS diagnosis and newborn screening; - Current management and treatment of GAMT- and AGAT-CCDS, and discussion of how to begin to approach treatments for CTD; and - Novel therapeutic approaches for CCDS, including working with scientists focused on related diseases that involve overlapping mechanisms. Responding to feedback from past similar meetings, educational sessions will cap both days of the Symposium, providing opportunities for scientists and affected individuals to learn from one another. In addition to covering recent research and sparking new dialogues, the 2nd CCDS Scientific+Family Symposium, a major priority of the conference is to walk away having moved more clearly toward 1) a consensus on best practices in the management and treatment of CCDS; 2) establishing endpoints and biomarkers, key to eventually launching clinical trials; 3) identifying strategies towards novel therapies; 4) strengthening and expanding the CCDS research and clinical community through the participation of junior scientists and scientists from underrepresented groups; 5) fostering collaborative basic and applied research in CCDS; and 6) increasing publications and general awareness about CCDS.